Literature DB >> 15204104

Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.

Hua Cao1.   

Abstract

A number of pharmacological agents are currently available for the induction of the fetal hemoglobin (Hb F) to treat the patients with sickle cell disease and beta-thalassemia. In the present review, we summarized the investigation and development of these Hb F-inducing agents and introduced histone deacetylase inhibitors as the new strategy to induce Hb F to treat the hemoglobin disorders Copyright 2004 Taylor and Francis Ltd

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15204104     DOI： 10.1080/10245330410001701512

Source DB:  PubMed          Journal:  Hematology        ISSN： 1024-5332            Impact factor:   2.269


  9 in total

Review 1.  Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia.

Authors:  Anna Rita Migliaccio; Dante Rotili; Angela Nebbioso; George Atweh; Antonello Mai
Journal:  Int J Biochem Cell Biol       Date:  2008-05-29       Impact factor: 5.085

2.  Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells.

Authors:  Shuaiying Cui; Katarzyna E Kolodziej; Naoshi Obara; Alexandra Amaral-Psarris; Jeroen Demmers; Lihong Shi; James Douglas Engel; Frank Grosveld; John Strouboulis; Osamu Tanabe
Journal:  Mol Cell Biol       Date:  2011-06-13       Impact factor: 4.272

3.  Changes in hemoglobin profile reflect autologous blood transfusion misuse in sports.

Authors:  Nicola Lamberti; Alessia Finotti; Jessica Gasparello; Ilaria Lampronti; Christel Zambon; Lucia Carmela Cosenza; Enrica Fabbri; Nicoletta Bianchi; Francesca Dalla Corte; Maurizio Govoni; Roberto Reverberi; Roberto Gambari; Fabio Manfredini
Journal:  Intern Emerg Med       Date:  2018-03-23       Impact factor: 3.397

4.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

5.  Hydroxyurea enhances SMN2 gene expression through nitric oxide release.

Authors:  Cheng Xu; Xin Chen; Susanna M Grzeschik; Madhuri Ganta; Ching H Wang
Journal:  Neurogenetics       Date:  2010-12-22       Impact factor: 2.660

Review 6.  Exploring epigenetic and microRNA approaches for γ-globin gene regulation.

Authors:  Athena Starlard-Davenport; Ashley Fitzgerald; Betty S Pace
Journal:  Exp Biol Med (Maywood)       Date:  2021-07-22

Review 7.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

8.  Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of {beta}-Thalassemia and Sickle-Cell Anemia.

Authors:  Nicoletta Bianchi; Cristina Zuccato; Ilaria Lampronti; Monica Borgatti; Roberto Gambari
Journal:  Evid Based Complement Alternat Med       Date:  2007-12-11       Impact factor: 2.629

9.  Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Authors:  Sean G Rudd; Nikolaos Tsesmetzis; Kumar Sanjiv; Cynthia Bj Paulin; Lakshmi Sandhow; Juliane Kutzner; Ida Hed Myrberg; Sarah S Bunten; Hanna Axelsson; Si Min Zhang; Azita Rasti; Petri Mäkelä; Si'Ana A Coggins; Sijia Tao; Sharda Suman; Rui M Branca; Georgios Mermelekas; Elisée Wiita; Sun Lee; Julian Walfridsson; Raymond F Schinazi; Baek Kim; Janne Lehtiö; Georgios Z Rassidakis; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Mats Heyman; Dan Grandér; Sören Lehmann; Thomas Lundbäck; Hong Qian; Jan-Inge Henter; Torsten Schaller; Thomas Helleday; Nikolas Herold
Journal:  EMBO Mol Med       Date:  2020-01-17       Impact factor: 12.137
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.